Evidence map›Paper›PMID 38658133›Full record

ArticleHuman vaccines & immunotherapeutics2024

Mucosal adjuvanticity and mucosal booster effect of colibactin-depleted probiotic

Hiroki Uchiyama, Toshifumi Kudo, Takehiro Yamaguchi, Nozomu Obana, Kenji Watanabe, Kimihiro Abe, Hidetaka Miyazaki, Masanori Toyofuku, Nobuhiko Nomura, Yukihiro Akeda and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Hiroki UchiyamaDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Toshifumi KudoDepartment of Vascular Surgery, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Takehiro YamaguchiDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Nozomu ObanaTsukuba Transborder Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Kenji WatanabeDepartment of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Kimihiro AbeDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Hidetaka MiyazakiDepartment of Oculoplastic, Orbital and Lacrimal Surgery, Aichi Medical University, Nagakute, Japan.
Masanori ToyofukuMicrobiology Research Center for Sustainability, University of Tsukuba, Tsukuba, Japan.
Nobuhiko NomuraMicrobiology Research Center for Sustainability, University of Tsukuba, Tsukuba, Japan.
Yukihiro AkedaDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Ryoma NakaoDepartment of Bacteriology I, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0002-4802-8518
National Institute of Infectious Diseases · JPTokyo Medical and Dental University · JPUniversity of Tsukuba · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a growing interest in development of novel vaccines against respiratory tract infections, due to COVID-19 pandemic. Here, we examined mucosal adjuvanticity and the mucosal booster effect of membrane vesicles (MVs) of a novel probiotic

Indexed as

Adjuvants, ImmunologicEscherichia coliImmunity, MucosalImmunization, SecondaryMice, Inbred BALB CPolyketidesProbioticsAdministration, IntranasalAnimalsCOVID-19 VaccinesFemaleImmunoglobulin AImmunoglobulin GImmunoglobulin MMicePeptidesAdjuvants, ImmunologiccolibactinCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GImmunoglobulin MPeptidesPolyketidesAdministration routecapsular polysaccharideheterologous prime-boost immunizationimmunogenicitymembrane vesiclesmucosal adjuvanticityprobiotic Escherichia colirespiratory tract infectionStreptococcus pneumoniae

Identifiers

PMID38658133
PMCPMC11057659
OpenAlexW4395462413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.